Activity of Thalidomide and Lenalidomide in Mantle Cell Lymphoma

Publisher： Karger

E-ISSN： 1421-9662|123|1|21-29

ISSN： 0001-5792

Source： Acta Haematologica, Vol.123, Iss.1, 2009-11, pp. : 21-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 224-235

John Wiley & Sons Inc

Access to resources Recommend Favorite

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 4, 2015-08 ,pp. : 496-503

John Wiley & Sons Inc

Access to resources Recommend Favorite

Involved‐field radiotherapy for patients with mantle cell lymphoma

By  

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, Vol. 59, Iss. 5, 2015-10 ,pp. : 631-639

John Wiley & Sons Inc

Access to resources Recommend Favorite

Composite Mantle‐Cell Lymphoma and Classical Hodgkin Lymphoma in a Very Old Adult

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 63, Iss. 4, 2015-04 ,pp. : 824-826

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma with Bendamustine and Rituximab

By  

Acta Haematologica, Vol. 126, Iss. 1, 2011-03 ,pp. : 40-43

Karger

Access to resources Recommend Favorite